Viral Vector Purification / Virus Purification Products Markets, 2030: Focus on Kit, Prepacked Column, Resin, Cassette, Filter Plate, Capsule, Reagent and Others

News provided by

Oct 13, 2020, 07:45 ET

DUBLIN, Oct. 13, 2020 /PRNewswire/ -- The "Viral Vector Purification / Virus Purification Products Market (kit, prepacked column, resin, cassette, filter plate, capsule, reagent and others), 2020-2030" report has been added to ResearchAndMarkets.com's offering.

The Viral Vector Purification / Virus Purification Products Market 2020-2030' report features an extensive study of various products available for viral vector purification, in addition to the current market landscape and future potential of product developers.

Overview

Since the approval and launch of cell and gene therapy products, such as Zolgensma (2019), ZYNTEGLO (2019), Luxturna (2017), KYMRIAH (2017) and YESCARTA (2017), there has been a significant increase in demand for viral vectors. Experts believe that the number of such therapies is likely to double over the next couple of years. It is also worth mentioning that this particular field of medical research received close to USD 10 billion in funding in 2019.

Currently, over 1,000 cell and gene therapy-related clinical trials are being conducted, worldwide. Genetic manipulation is a basic requirement of cell and gene therapy development, and, as a result, gene delivery vectors are considered to be of utmost importance in this domain. So far, viral vectors (such as those based on adeno-associated viruses (AAV), adenoviruses, lentivirus, retroviruses and other viruses) have been shown to be the most versatile gene delivery tools available, having demonstrated high transfection efficiencies in both preclinical and clinical settings.

Further, taking into account the therapeutic efficacy and low side effects profiles of cell and gene therapies, the demand for such interventions is anticipated to grow at a rapid pace, resulting in a proportional increase in need for appropriate vector systems, as well. However, viral vector development and manufacturing is a complex and cost intensive process. One of the primary concerns associated with viral vector production is related to yield; in fact, a singular batch run is estimated to incur losses of up to 70% during the purification step alone.

A number of techniques are presently used for viral vector purification. Over the years, size-based viral purification strategies, such as density-gradient ultracentrifugation, ultrafiltration, precipitation and size-exclusion chromatography (SEC), have become part of the accepted industry standard. However, recently, stakeholders have begun relying more on affinity chromatography-based purification regimens, given its robustness and high selectivity. Presently, several companies claim to offer a diverse range of virus purification solutions, including, filter plates, prepacked chromatography columns and resins, and consolidated kits, for viral vector (virus) purification. As indicated earlier, downstream processing of viral vector products is challenging.

Scope of the Report

An overview of the current market landscape of companies providing products for purification of viruses / viral vectors, using different techniques, such as chromatography, centrifugation and filtration. It features information on the type of product (kit, prepacked column, resin, cassette, filter plate, capsule and reagent), type of purification technique (chromatography, centrifugation and filtration), scale of operation (lab-scale, clinical and commercial), type of viral vector (AAV, adenovirus, lentivirus, retrovirus and others) and details on other physical and operational parameters of the product (such as matrix, pore size, volume of bed, flow rate, operating pressure, working temperature, pH, filtration area and process time).

In addition, the chapter includes information on the purification product developers, including details on the year of establishment, company size and location of headquarters. Elaborate profiles of key players, including an overview of the company, product portfolio (viral vector purification products), recent developments and an informed future outlook.

An analysis evaluating the potential strategic partners (comprising of viral vector-based therapy developers and viral vector manufacturers) for viral vector purification product developers, based on several parameters, such as type of viral vector, developer strength, operational strength, therapeutic area, strength of clinical pipeline and strength of preclinical pipeline.

A clinical trial analysis of completed, ongoing and planned studies of various viral vector-based cell therapies, gene therapies and vaccines (approved / under development). It features detailed analyses of clinical studies of different viral-vector based therapies on the basis of their registration year, phase of development, trial status, type of therapy, therapeutic area, type of sponsor/collaborator, geographical location, number of patients enrolled and key players.

An informed estimate of the annual clinical and commercial demand (in terms of number of patients) for viral vectors, taking into account the marketed gene-based therapies and clinical studies evaluating vector-based therapies; the analysis also takes into consideration various relevant parameters, such as target patient population, dosing frequency and dose strength. Further, the demand has been segregated on the basis of type of viral vector, type of therapy, therapeutic are and geographical location.
A case study on tangential flow filtration (TFF), highlighting the role, advantages and disadvantages of the technique for purification of viral vectors; the chapter features details of products used for TFF, including product type, scale of operation, membrane material, flow rate and filtration area.

A case study featuring the viral vector manufacturers providing commercial scale production, highlighting details on their year of establishment, company size, type of viral vector (AAV, adenovirus, lentivirus, retrovirus and others), purpose of production (in-house and contract-basis), and location of headquarters and manufacturing facilities.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for viral vector purification product developers, over the coming decade. Based on various parameters, such as the likely increase in number of clinical studies related to viral vector-based therapies, anticipated growth in target patient population, existing price variations across different purification techniques, and the success of cell and gene therapy products (considering both approved and late-stage clinical candidates), we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2020-2030.

Companies Mentioned

4D Molecular Therapeutics
Abbott
Abeona Therapeutics
Actus Therapeutics
Adaptimmune Therapeutics
Addgene
Advanced BioScience Laboratories
Advantagene
Advaxis
Advent
Adverum Biotechnologies
Agilent Technologies
Allergan
Allife Medical Science and Technology
Allogene Therapeutics
AlphaVax
ALSTEMlstem
Altor BioScience
American Gene Technologies
Amgen
Amicus Therapeutics
AMSBIO
Anaeropharma Science
Angionetics
apceth Biopharma
Apic Bio
Applied Biological Materials
Applied Genetic Technologies Corporation
Applied Viromics
Arthrogen
Aruvant Sciences
Asklepios BioPharmaceutical
Atara Biotherapeutics
ATVIO Biotechnology
Audentes Therapeutics
Aurora Biopharma
Autolus
AVROBIO
Axovant
Batavia Biosciences
Bayer
Baylor College of Medicine
Beijing Biohealthcare Biotechnology
Beijing Doing Biomedical
Beijing Immunochina Medical Science & Technology
Beijing Mario Biotech
Beijing Sanwater Biological Technology
Bellicum Pharmaceuticals
BIA Separations
Bioceltech Therapeutics
Biogen
BioMarin Pharmaceutical
BioNTech Innovative Manufacturing Services
Bio-Rad
BioReliance
Bioverativ
Biovian
BioVision
Blue Sky BioServices
bluebird bio
Brammer Bio
Bristol-Myers Squibb
Carina Biotech
CARsgen Therapeutics
Castle Creek Pharmaceuticals
Celgene
Cell Biolabs
Cellectis
CELLforCURE
CellGenTech
Cellular Biomedicine
Celonic
Celyad
Centre for Process Innovation
CEVEC Pharmaceuticals
China Immunotech
Clean Cells
Cobra Biologics
Cold Genesys
Creative Biogene
Creative Biolabs
CRISPR Therapeutics
Cytiva
Cytovance Biologics
Daiichi Sankyo
DNAtrix
Editas Medicine
Emergent BioSolutions
Epeius Biotechnologies
Errant Gene Therapeutics
Esteve
ExcellGene
Fibrocell
FinVector
FIT Biotech
FKD Therapies
Flash Therapeutics
Flexion Therapeutics
Formula Pharmaceuticals
Fosun Pharma
Freeline Therapeutics
FUJIFILM Diosynth Biotechnologies
GE Healthcare
GEG Tech
Gene Biotherapeutics
GeneCure Biotechnologies
GeneDetect
Genelux Corporation
Genethon
Genezen Laboratories
GenIbet Biopharmaceuticals
GenSight Biologics
GenVec
GlaxoSmithKline
Gracell Biotechnologies
Guangdong Xiangxue Precision Medical Technology
Guangdong Zhaotai InVivo Biomedicine
Guangzhou Anjie Biomedical Technology
Guangzhou Double Bioproducts
Guangzhou FineImmune Biotechnology
Guangzhou YiYang Biological Technology
Gyroscope Therapeutics
Hebei Senlang Biotechnology
Hemera Biosciences
Henan Hualong Biotechnology Company
Herantis Pharma
Holostem Terapie Avanzate
Homology Medicines
Horama
Hrain Biotechnology
Hunan Zhaotai Yongren Biotech
Hunan Zhaotai Yongren Medical Innovation
iCAR Bio Therapeutics
iCarTAB BioMed
iCell Gene Therapeutics
ID Pharma
Immatics
Immunocore
Innovative Cellular Therapeutics
Janssen Pharmaceuticals
Juno Therapeutics
JW Therapeutics
KAEDI
Kite Pharma
Kolon TissueGene
Krystal Biotech
Kuur Therapeutics
Lentigen Technology
Leucid Bio
Lion TCR
Lokon Pharma
Lonza
Lysogene
Marino Biotechnology
Marsala Biotech
Mayflower Bioscience
Medigene
MedImmune
MeiraGTx
Merck
Milo Biotechnology
Miltenyi Biotec
MingJu Therapeutics
MolMed
Momotaro-Gene
MultiVir
Mustang Bio
Myonexus Therapeutics
Nanjing Legend Biotech
NEC
Neuralgene
Neurocrine Biosciences
Nightstar Therapeutics
Nikon CeLL innovation
Norgen Biotek
Novartis
Novasep
Oncolys BioPharma
ORCA Therapeutics
Orchard Therapeutics
Oxford BioMedica
Oxford Genetics
OZ Biosciences
Pall Biotech
Paragon Gene Therapy
PeriphaGen
PersonGen BioTherapeutics
Pfizer
Pinze Lifetechnology
Precigen
Precision BioSciences
ProBioGen
ProMab Biotechnologies
PsiOxus Therapeutics
PTC Therapeutics
Regeneron Pharmaceuticals
REGENXBIO
ReiThera
Renova Therapeutics
Rocket Pharmaceuticals
Rubius Therapeutics
SAB Technology
Sangamo Therapeutics
Sanofi
Sarepta Therapeutics
Sartorius
Servier
Shanghai Bioray Laboratory
Shanghai GeneChem
Shanghai Longyao Biotechnology
Shanghai Sinobioway Sunterra Biotechnology
Shanghai Sunway Biotech
Shanghai Unicar-Therapy Bio-medicine Technology
Shenzhen BinDeBio
Shenzhen SiBiono GeneTech
Shionogi
SignaGen Laboratories
SillaJen
Sinobioway Cell Therapy
SIRION Biotech
Solid Biosciences
Sorrento Therapeutics
SOTIO
Spark Therapeutics
System Biosciences
Takara Bio
Takeda
Targovax
Tasly Biopharmaceuticals
TCR2 Therapeutics
TCRCure Biopharma
The Beijing Pregene Science and Technology
The Pregene (ShenZhen) Biotechnology
TheraBiologics
Theravectys
Thermo Fisher Scientific
Tianjin Mycure Medical Technology
Timmune
Tmunity Therapeutics
Tocagen
Transgene
Ultragenyx Pharmaceutical
Union Stem Cell & Gene Engineering
uniQure
Unum Therapeutics
Vascular Biogenics
VCN Biosciences
Vector Biolabs
Vertex Pharmaceuticals
Vessl
Vibalogics
Vigene Biosciences
ViralGEN
Virapur
ViraQuest
Virovek
Virttu Biologics
VIVEbiotech
Voyager Therapeutics
Wuhan Sian Medical Technology
WuXi AppTec
Wyvern Pharmaceuticals
Xiangxue Life Sciences
Xiangxue Pharmaceutical
XyloCor Therapeutics
Yake Biotechnology
Yposkesi
Ziopharm Oncology

For more information about this report visit https://www.researchandmarkets.com/r/7vgthw

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets